SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma rises as its arm enters into agreement to divest US manufacturing unit

15 Dec 2015 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 774.55, up by 5.95 points or 0.77 % from its previous closing of Rs. 768.60 on the BSE.

The scrip opened at Rs. 776.50 and has touched a high and low of Rs. 781.10 and Rs. 773.50 respectively. So far 58665 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 706.40 on 24-Nov-2015.

Last one week high and low of the scrip stood at Rs. 779.50 and Rs. 734.40 respectively. The current market cap of the company is Rs. 186769.32 crore.

The promoters holding in the company stood at 54.71 % while Institutions and Non-Institutions held 35.62 % and 9.68 % respectively.

As a part of its manufacturing consolidation in the US, Sun Pharmaceutical Industries’ one of wholly owned subsidiaries has entered into an agreement with Nostrum Laboratories Inc. (Nostrum) for the divestment of the Bryan (Ohio) unit in the US.

As a part of the agreement, the Sun Pharma subsidiary has divested this unit as a going concern along with the employees and related products to Nostrum. During the divestment process, Sun Pharma was cognizant that the interests of its employees working in the unit were not compromised.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.

 

Sun Pharma Inds. Share Price

1863.90 16.60 (0.90%)
11-May-2026 10:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1863.90
Dr. Reddys Lab 1279.75
Cipla 1338.65
Zydus Lifesciences 935.55
Lupin 2250.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×